Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)

Conclusion: The primary mRSS endpoint was not met. A clinically relevant difference in FVC was seen for TCZ vs PBO, with preservation of lung function.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Denton, C. P., Lin, C. J. F., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Batalov, A., Butrimiene, I., Carreira, P., Matucci-Cerinic, M., Distler, O., Martinovic Kaliterna, D., Mihai, C.-M., Mogensen, M., Olesinska, M., Pope, J. E., Riemekasten, G., Ro Tags: ILD/DPLD of known origin Source Type: research